Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of “Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GHGet Rating) have earned an average recommendation of “Buy” from the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $140.36.

GH has been the subject of several recent analyst reports. SVB Leerink reduced their price objective on shares of Guardant Health from $170.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. Zacks Investment Research cut Guardant Health from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. Wells Fargo & Company dropped their price target on Guardant Health from $150.00 to $115.00 and set an “overweight” rating on the stock in a research note on Thursday, February 24th. Morgan Stanley lowered their target price on shares of Guardant Health from $125.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday, February 24th. Finally, Stifel Nicolaus decreased their price target on shares of Guardant Health from $160.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, February 24th.

NASDAQ:GH opened at $31.33 on Wednesday. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -7.60 and a beta of 0.70. The company has a quick ratio of 5.57, a current ratio of 5.72 and a debt-to-equity ratio of 1.76. Guardant Health has a 52 week low of $28.50 and a 52 week high of $133.82. The company has a fifty day simple moving average of $61.73 and a two-hundred day simple moving average of $79.59.

Guardant Health (NASDAQ:GHGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($1.21) EPS for the quarter, hitting analysts’ consensus estimates of ($1.21). Guardant Health had a negative return on equity of 58.70% and a negative net margin of 107.20%. The business had revenue of $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. During the same period in the previous year, the company posted ($1.06) earnings per share. The business’s revenue for the quarter was up 22.2% on a year-over-year basis. On average, analysts expect that Guardant Health will post -4.88 EPS for the current year.

In other Guardant Health news, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $58.74, for a total transaction of $289,823.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 5.80% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Capital Research Global Investors lifted its stake in Guardant Health by 144.9% during the third quarter. Capital Research Global Investors now owns 5,286,792 shares of the company’s stock worth $660,902,000 after purchasing an additional 3,128,063 shares during the last quarter. Morgan Stanley raised its holdings in shares of Guardant Health by 31.0% during the third quarter. Morgan Stanley now owns 5,560,641 shares of the company’s stock valued at $695,134,000 after buying an additional 1,315,317 shares during the last quarter. Norges Bank bought a new position in Guardant Health in the 4th quarter worth approximately $85,407,000. Capital International Investors raised its stake in Guardant Health by 38.0% during the 4th quarter. Capital International Investors now owns 2,971,384 shares of the company’s stock valued at $297,198,000 after acquiring an additional 818,309 shares in the last quarter. Finally, Casdin Capital LLC bought a new position in shares of Guardant Health in the fourth quarter worth $79,016,000. 93.69% of the stock is owned by institutional investors.

About Guardant Health (Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Further Reading

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.